
Sign up to save your podcasts
Or
Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.
Read the full article:
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
5
22 ratings
Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.
Read the full article:
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
131 Listeners
288 Listeners
323 Listeners
46 Listeners
494 Listeners
14 Listeners
86 Listeners
27 Listeners
21 Listeners
186 Listeners
512 Listeners
132 Listeners
17 Listeners
364 Listeners
77 Listeners